Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 726 to 750 of 872

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanomaTA321
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosisTA320
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimenTA316
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromesTA317
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanomaTA319
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failureTA314
Canagliflozin in combination therapy for treating type 2 diabetesTA315
Teriflunomide for treating relapsing–remitting multiple sclerosisTA303
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantationTA311
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitisTA308
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hipTA304
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionTA305
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphomaTA306
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis CTA106
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)TA302
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young peopleTA300
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis CTA75
Pazopanib for the first-line treatment of advanced renal cell carcinomaTA215
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorderTA292
Aflibercept solution for injection for treating wet age‑related macular degenerationTA294
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolismTA287
Mirabegron for treating symptoms of overactive bladderTA290
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancerTA284

Results per page

  1. 10
  2. 25
  3. 50
  4. All